Femasys (FEMY) News Today $1.33 -0.03 (-2.21%) (As of 10/31/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeedOctober 31 at 4:38 PM | finance.yahoo.comStrategic Partnerships and Market Potential Drive Positive Outlook for FemaSeed Amidst RisksOctober 31 at 6:18 AM | markets.businessinsider.comFemasys announces partnership with Boston IVFOctober 31 at 6:18 AM | markets.businessinsider.comFemasys Advances in Women’s Health InnovationOctober 29 at 10:00 PM | markets.businessinsider.comFemasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education ProgramOctober 10, 2024 | finance.yahoo.comFemasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education ProgramOctober 10, 2024 | globenewswire.comFemasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitOctober 9, 2024 | markets.businessinsider.comFemasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility TreatmentsOctober 2, 2024 | markets.businessinsider.comFemasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility TreatmentsOctober 2, 2024 | globenewswire.comFemasys Announces Infertility Clinic Customers from Coast to CoastSeptember 18, 2024 | globenewswire.comFemasys’s Strategic Expansion and Market Potential Bolster Buy RatingSeptember 13, 2024 | markets.businessinsider.comFemasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)September 12, 2024 | benzinga.comFemasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish MarketSeptember 11, 2024 | globenewswire.comFemasys Receives 510(k) Clearance From FDA To Market FemChec For Fallopian Tube DiagnosisSeptember 10, 2024 | markets.businessinsider.comFemasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube CheckSeptember 9, 2024 | globenewswire.comFemasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual MeetingSeptember 5, 2024 | markets.businessinsider.comFemasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual MeetingSeptember 5, 2024 | globenewswire.comFemasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comFemasys Inc.: Femasys Announces CE Mark and Canadian Approval for FemVue MINI, a Fallopian Tube Assessment SolutionAugust 29, 2024 | finanznachrichten.deFemasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment SolutionAugust 29, 2024 | globenewswire.comFemasys Hosts Congresswoman Lucy McBath at Georgia HeadquartersAugust 27, 2024 | globenewswire.comFemasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate UpdateAugust 8, 2024 | globenewswire.comFemasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in AmsterdamJune 27, 2024 | globenewswire.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot InitiativeMay 17, 2024 | finance.yahoo.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot InitiativeMay 17, 2024 | globenewswire.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy CouncilMay 16, 2024 | finance.yahoo.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy CouncilMay 16, 2024 | globenewswire.comFemasys’s Buy Rating Affirmed by Analyst Jason McCarthy on FemaSeed’s Market Success and Robust Clinical TrialsMay 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and Femasys (FEMY)May 9, 2024 | markets.businessinsider.comFEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | investorplace.comFemasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate UpdateMay 9, 2024 | globenewswire.comFemasys Expands Commercial Management Team with Addition of Experienced New HiresMay 7, 2024 | globenewswire.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare InitiativesApril 18, 2024 | finance.yahoo.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare InitiativesApril 18, 2024 | globenewswire.comFemasys (FEMY) Price Target Increased by 5.41% to 9.95April 17, 2024 | msn.comFemasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 31, 2024 | finance.yahoo.comFEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023March 28, 2024 | investorplace.comFemasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate UpdateMarch 28, 2024 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Femasys (FEMY), BioNTech SE (BNTX)March 21, 2024 | markets.businessinsider.comFemasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment LandscapeMarch 21, 2024 | globenewswire.comFemasys Discloses Positive Data from FemaSeed TrialMarch 21, 2024 | marketwatch.comFemasys Inc.: Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of InfertilityMarch 20, 2024 | finanznachrichten.deFemasys Announces Positive Data For FemaSeed Trial To Enhance Fertilization In WomenMarch 20, 2024 | markets.businessinsider.comFemasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of InfertilityMarch 20, 2024 | globenewswire.comFemasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024March 13, 2024 | finance.yahoo.comThinking about buying stock in Onespan, Avinger, Lithium Americas, Geron, or Femasys?March 9, 2024 | morningstar.comFemasys Inc.: Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility SolutionMarch 6, 2024 | finanznachrichten.deFemasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility SolutionMarch 6, 2024 | globenewswire.comFemasys Inc.: Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVFFebruary 28, 2024 | finanznachrichten.deFemasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVFFebruary 28, 2024 | finance.yahoo.com Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Banking failure dead ahead (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. FEMY Media Mentions By Week FEMY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FEMY News Sentiment▼0.800.68▲Average Medical News Sentiment FEMY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FEMY Articles This Week▼61▲FEMY Articles Average Week Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sensus Healthcare News Edap Tms News Pro-Dex News FONAR News Monogram Orthopaedics News Modular Medical News Hyperfine News TELA Bio News Vivani Medical News Alpha Pro Tech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FEMY) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.